M. Gilles

Pre-clinical evaluation of antiviral activity of nitazoxanide against Sars-CoV-2

This study evaluates nitazoxanide's antiviral activity against SARS-CoV-2 in vitro and in vivo, finding that its standard dosage is ineffective due to insufficient drug concentration in target organs.

Niclosamide shows strong antiviral activity in a human airway model of SARS-CoV-2 infection and a conserved potency against the UK B.1.1.7 and SA B.1.351 variant

This study shows niclosamide is effective against SARS-CoV-2 and its variants in a human airway model, supporting its potential as a COVID-19 therapy.

Replicative fitness SARS-CoV-2 20I/501Y.V1 variant in a human reconstituted bronchial epithelium

This study compares the replication efficiency of the SARS-CoV-2 20I/501Y.V1 variant with an ancestral strain in human bronchial epithelium models, finding the variant outcompetes the ancestral strain in competition experiments.

Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2

This study evaluates Imatinib's antiviral potential against SARS-CoV-2 in vitro and in vivo, finding it ineffective in key models despite plasma and lung concentrations.

Evaluation of heating and chemical protocols for inactivating SARS-CoV-2

The paper evaluates heating and chemical protocols for inactivating SARS-CoV-2, finding that Triton-X100 in guanidinium thiocyanate buffers achieves 6-log reduction, while heating protocols affect RNA detection.

In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication

This study screens an FDA-approved chemical library to identify potential inhibitors of SARS-CoV-2 replication in vitro, finding several compounds with antiviral potency.

Live Zika virus chimeric vaccine candidate based on a yellow fever 17-D attenuated backbone

This paper develops a chimeric Zika virus vaccine using a yellow fever 17-D backbone and shows it induces neutralizing antibodies and protects mice against ZIKV challenge.